In a report released today, Anthony Vendetti from Maxim Group maintained a Buy rating on Viveve Medical Inc (VIVE – Research Report), with a price target of $6. The company’s shares closed yesterday at $0.87, equals to its 52-week low of $0.87.
“4Q18 loss per share was slightly wider-than-expected on revenue that was relatively inline with the preannouncement.”
According to TipRanks.com, Vendetti is a 4-star analyst with an average return of 6.1% and a 49.6% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Ellex Medical Lasers Limited, Restoration Robotics Inc, and Ra Medical Systems Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Viveve Medical Inc with a $3.75 average price target, representing a 328.8% upside. In a report released today, Mizuho Securities also maintained a Buy rating on the stock with a $4 price target.
Based on Viveve Medical Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $12.3 million. In comparison, last year the company had a GAAP net loss of $10.22 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Viveve Medical, Inc. engages in the provision of health products. Its activities include development and distribution of women’s health solutions. Its products include non-surgical, non-ablative medical device that remodels collagen and restores vaginal tissue. The company was founded on March 3, 1987 and is headquartered Englewood, CO.